Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: Comparative measurements using EF5 binding and the Eppendorf needle electrode

International Journal of Radiation Oncology Biology Physics

Volumn 46, Issue 4, 2000, Pages 1005-1017

  Jenkins, W Timothy ^a   Evans, Sydney M ^a   Koch, Cameron J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

9L Glioma; EF5; Eppendorf needle electrode; Hypoxia; Morris 7777 hepatoma; Therapy resistance; Tumor heterogeneity; Tumor necrosis

Indexed keywords

2 NITROIMIDAZOLE DERIVATIVE; OXYGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ELECTRODE; GLIOMA; HYPOXIA; LIVER CELL CARCINOMA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE NECROSIS; TUMOR NECROSIS;

ANIMALS; CELL HYPOXIA; ETANIDAZOLE; GLIOMA; HYDROCARBONS, FLUORINATED; INDICATORS AND REAGENTS; ION-SELECTIVE ELECTRODES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NECROSIS; OXYGEN; PARTIAL PRESSURE; RADIOBIOLOGY; RATS; RATS, INBRED F344; TUMOR CELLS, CULTURED;

EID: 0033997568     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00342-9     Document Type: Article

References (48)

1. Brizel D.M., Scully S.P., Harrelson J.M., et al. Tissue oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
2. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 38:1997;285-289.
3. Hockel M., Knoop C., Schlenger K., et al. Intratumor pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 26:1993;45-50.
4. Hockel M., Schlenger K., Aral B., et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515.
5. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 41:1996;31-39.
6. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 48:1998;149-156.
7. Hirst D.G., Hazlehurst J.L., Brown J.M. Changes in misonidazole binding with hypoxic fraction in mouse tumors. Int J Radiat Biol Oncol Phys. 11:1984;1349-1355.
8. Horsman M.R., Khalil A.A., Siemann D.W., et al. Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. Int J Radiat Oncol Biol Phys. 29:1994;4-442.
9. Hu Q., Kavanagh M.-C., Newcombe D., et al. Detection of hypoxic fractions in murine tumors by comet assay Comparison with other techniques . Radiat Res. 144:1995;266-275.
10. Kavanagh M.C., Sun A., Hu Q., et al. Comparing techniques of measuring tumor hypoxia in different murine tumors Eppendorf pO2 histograph, [3H]misonidazole binding and paired survival assay . Radiat Res. 145:1996;491-500.
11. Li S.-J., Jin G.-Y., Fish B.L., et al. Correlation of radiobiological assays of hypoxic fraction with phosphorous-31 magnetic resonance spectroscopy across multiple tumor lines. Radiat Res. 143:1995;45-53.
12. Olive P.L., Vikse C.M., Durand R.E. Hypoxic fractions measured in murine tumors and normal tissues using the comet assay. Int J Radiat Oncol Biol Phys. 29:1994;487-491.
13. Wendland M.F., Iyer S.B., Fu K.K., et al. Correlations between in vivo 31PMRS measurements, tumor size, cell survival, and hypoxic fraction in the murine EMT6 tumor. Magn Reson Med. 25:1992;217-232.
14. Stone H.B., Brown J.M., Phillips T.L., et al. Oxygen in human tumors Correlations between methods of measurement and response to therapy . Radiat Res. 136:1993;422-434.
15. Lord E.M., Harwell L.W., Koch C.J. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 53:1993;5271-5276.
16. Koch C.J., Evans S.M., Lord E.M. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide] Analysis of drug adducts by fluorescent antibodies vs. bound radioactivity . Br J Cancer. 72:1995;869-874.
17. Evans S.M., Jenkins W.T., Joiner B., et al. 2-nitroimidazole (EF5) binding predicts radiation sensitivity in individual 9L subcutaneous tumors. Cancer Res. 56:1996;405-411.
18. Lee J., Siemann D.W., Koch C.J., et al. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Int J Cancer. 67:1996;372-378.
19. Woods M.R., Lord E.M., Koch C.J. Detection of individual hypoxic cells in multicellular spheroids by flow cytometery using the 2-nitroimidazole EF5, and monoclonal antibodies. Int J Radiat Oncol Biol Phys. 34:1996;93-101.
20. Leith J.T., Schilling W.A., Wheeler K.T. Cellular radiosensitivity of a rat brain tumor. Cancer. 35:1975;1545-1550.
21. Wallen C.A., Michaelson S.M., Wheeler K.T. Evidence for an unconventional radiosensitivity of rat 9L subcutaneous tumors. Radiat Res. 85:1980;529-541.
22. Morris H.P. Studies on the development, biochemistry and biology of experimental hepatomas. Adv Cancer Res. 9:1965;227-302.
23. Morris H.P., Wagner B.P. Induction and transplantation of rat hepatomas with different growth rat (including "minimal deviation" hepatomas). Meth Cancer Res. 4:1968;125-152.
24. Southwick P.L., Ernst L.A., Tauriello E.W., et al. Cyanine dye labeling reagents - carboxymethylindocyanine succinimidyl esters. Cytology. 11:1990;418-430.
25. Evans S.M., Koch C.J., Joiner B., et al. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br J Cancer. 72:1995;875-882.
26. Thomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 9:1955;539-579.
27. Thews O., Kelleher D.K., Vaupel P.W. pO2-mapping of experimental rat tumors Visualization and statistical analysis . Vaupel P.W., Kelleher D.K., Gunderoth M. Tumor oxygenation. 1995;27-38 Gustav Fischer Verlag, Stuttgart.
28. Khalil A.A., Horsman M.R., Overgaard J. The importance of determining necrotic fraction when studying the effect of tumour volume on tissue oxygenation. Acta Oncol. 34:1995;297-300.
29. De Jaeger K., Merlo F.M., Kavanagh M.C., et al. Heterogeneity of tumor oxygenation Relationship to tumor necrosis, tumor size, and metastasis . Int J Radiat Oncol Biol Phys. 42:1998;717-721.
30. Barker F.G.D., Davis R.L., Chang S.M., et al. Necrosis as a prognostic factor in glioblastoma multiforme. Cancer. 77:1996;1161-1166.
31. Choong P.F., Ferno M., Akerman M., et al. Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int J Cancer. 69:1996;268-272.
32. Chua D.T., Sham J.S., Kwong D.L., et al. Evaluation of cervical nodal necrosis in nasopharyngeal carcinoma by computed tomography Incidence and prognostic significance . Head Neck. 19:1997;266-275.
33. Gilchrist K.W., Gray R., Fowble B., et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer A 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients . J Clin Oncol. 11:1993;1929-1935.
34. Kessler R., Gasser B., Massard G., et al. Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer. Ann Thorac Surg. 62:1996;1489-1493.
35. Mulcahy H.E., Toner M., Patchett S.E., et al. Identifying stage B colorectal cancer patients at high risk of tumor recurrence and death. Dis Colon Rectum. 40:1997;326-331.
36. Nixon A.J., Neuberg D., Hayes D.F., et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 12:1994;888-894.
37. Barranco S.C., Perry R.R., Durm M.E., et al. Intratumor variability in prognostic indicators may be the cause of conflicting estimates of patient survival and response to therapy. Cancer Res. 54:1994;5351-5356.
38. Laughlin K.M., Evans S.M., Jenkins W.T., et al. Biodistribution of the nitroimidazole EF5 [2-(2-nitro-1H-imidazole-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide] in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther. 277:1996;1049-1057.
39. Nozue M., Lee I., Yuan F., et al. Interlaboratory variation in oxygen tension measurement by Eppendorf "histograph" and comparison with hypoxic marker. J Surg Oncol. 66:1997;30-38.
40. Cline J.M., Rosner G.L., Raleigh J.A., et al. Quantification of CCI-103F labeling heterogeneity in canine solid tumors. Int J Radiat Oncol Biol Phys. 37:1997;655-662.
41. Wouters B.G., Brown J.M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiation therapy. Radiat Res. 147:1997;541-550.
42. Evans S.M., Laughlin K.M., Pugh C.R., et al. Use of power Doppler ultrasound-guided biopsies to locate regions of tumour hypoxia. Br J Cancer. 76:1997;1308-1314.
43. Aboagye E.O., Maxwell R.J., Kelson A.B., et al. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia. Cancer Res. 57:1997;3314-3318.
44. Evans SM, Kachur AV, Shiue C-Y; et al. Non-invasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med. In press.
45. Jin G.Y., Li S.J., Moulder J.E., et al. Dynamic measurements of hexafluoromisonidazole (CCI-103F) retention in mouse tumours by 1H/19F magnetic resonance spectroscopy. Int J Radiat Biol. 58:1990;1025-1034.
46. Koch C.J., Raleigh J.A. Radiolytic reduction of protein and non-protein disulfides in the presence of formate A chain reaction . Arch Biochem Biophys. 287:1991;75-84.
47. Koh W.-J., Rasey J.S., Evans M.L., et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Biol Oncol Phys. 22:1991;199-212.
48. Parliament M.B., Chapman J.D., Urtasun R.C., et al. Non-invasive assessment of human tumour hypoxia with I-iodoazomycin arabinoside Preliminary report of a clinical study . Br J Cancer. 65:1992;90-95.